tiprankstipranks
Trending News
More News >
Calidi Biotherapeutics (CLDI)
:CLDI
US Market
Advertisement

Calidi Biotherapeutics (CLDI) Stock Statistics & Valuation Metrics

Compare
308 Followers

Total Valuation

Calidi Biotherapeutics has a market cap or net worth of $21.82M. The enterprise value is $11.95M.
Market Cap$21.82M
Enterprise Value$11.95M

Share Statistics

Calidi Biotherapeutics has 34,520,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,520,580
Owned by Insiders3.35%
Owned by Institutions11.72%

Financial Efficiency

Calidi Biotherapeutics’s return on equity (ROE) is -14.43 and return on invested capital (ROIC) is -238.61%.
Return on Equity (ROE)-14.43
Return on Assets (ROA)-1.56
Return on Invested Capital (ROIC)-238.61%
Return on Capital Employed (ROCE)-4.65
Revenue Per Employee0.00
Profits Per Employee-793.18K
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio2.26
Price to Fair Value6.00
Price to FCF-2.02
Price to Operating Cash Flow-1.74
PEG Ratio-0.01

Income Statement

In the last 12 months, Calidi Biotherapeutics had revenue of 0.00 and earned -22.14M in profits. Earnings per share was -2.97.
Revenue0.00
Gross Profit0.00
Operating Income-21.78M
Pretax Income-22.20M
Net Income-22.14M
EBITDA-21.78M
Earnings Per Share (EPS)-2.97

Cash Flow

In the last 12 months, operating cash flow was -31.01M and capital expenditures -896.00K, giving a free cash flow of -31.90M billion.
Operating Cash Flow-31.01M
Free Cash Flow-31.90M
Free Cash Flow per Share-0.92

Dividends & Yields

Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.56
52-Week Price Change-64.77%
50-Day Moving Average0.39
200-Day Moving Average0.95
Relative Strength Index (RSI)59.07
Average Volume (3m)28.42M

Important Dates

Calidi Biotherapeutics upcoming earnings date is Aug 19, 2025, After Close (Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date

Financial Position

Calidi Biotherapeutics as a current ratio of 1.08, with Debt / Equity ratio of 59.14%
Current Ratio1.08
Quick Ratio1.08
Debt to Market Cap0.41
Net Debt to EBITDA0.12
Interest Coverage Ratio-23.34

Taxes

In the past 12 months, Calidi Biotherapeutics has paid 14.00K in taxes.
Income Tax14.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Calidi Biotherapeutics EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.34.
EV to Sales0.00
EV to EBITDA-0.31
EV to Free Cash Flow-0.34
EV to Operating Cash Flow-0.34

Balance Sheet

Calidi Biotherapeutics has $1.24M in cash and marketable securities with $11.71M in debt, giving a net cash position of $10.47M billion.
Cash & Marketable Securities$1.24M
Total Debt$11.71M
Net Cash$10.47M
Net Cash Per Share$0.30
Tangible Book Value Per Share$0.25

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Calidi Biotherapeutics is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.50
Price Target Upside296.83% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast64.19%

Scores

Smart Score3
AI Score37.2
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis